Clarity Pharmaceuticals (CU6) H2 2025 earnings summary

Executive summary

• Achieved significant clinical milestones, including progression of two Phase III trials for SAR-bisPSMA in prostate cancer and positive Phase II data for SARTATE (NETs) and SAR-Bombesin (prostate cancer).

• Raised $203.6 million in a placement, strengthening the cash position to $277 million pro-forma at June 2025.

• Refocused strategy on high-value, high-probability clinical programs to extend cash runway amid market volatility.

• Expanded manufacturing and supply chain agreements to support anticipated commercial rollout.

Financial highlights

• Net loss for the year ended 30 June 2025 was $64.3 million, up from $42.3 million in 2024, driven by increased R&D expenditure.

• Research and development expenses rose to $66.9 million (up $21.1 million year-over-year).

• Cash and financial assets at 30 June 2025 totaled $84.1 million, with a pro-forma cash balance of $277 million post-placement.

• No dividends declared or paid.

Outlook and guidance

• Well-funded to support ongoing clinical trials and regulatory submissions through FY2026.

• Focus remains on progressing SAR-bisPSMA, SARTATE, and SAR-Bombesin towards commercialisation, with additional assets in the pipeline.

• Anticipates further clinical data readouts and potential Phase III trial initiations in the coming year.